Document is current

Article History

Received: 24 February 2026

Accepted: 27 April 2026

First Online: 2 May 2026

Declarations

:

: This study was reviewed by the North Star Review Board (Application #NB400246). It was granted an exemption determination from the Common Rule under 45 CFR 46.104(d)(2), due to the anonymous nature of the study.

: Digital informed consent was obtained from all individual participants included in the study.

: Celeste Suart, Aimee Alcott, Lori Shogren, Kelsey Trace, and Lauren Moore are full-time employees of the National Ataxia Foundation.Liana Rosenthal receives research funding support from the NINDS, the Daniel B. and Florence E. Green Family Foundation, and the Macks Family Foundation. She receives additional programmatic support from the Gordon and Marilyn Macklin Foundation. She receives salary support for her role as the site Principal Investigator for research studies with Biohaven Pharmaceuticals, Pfizer, and EIP Pharma and for serving on the Clinical Events Committee for a research study with Functional Neuromodulation. She also serves on the steering committees for the Parkinson Study Group’s research study with both UCB and Bial Pharmaceuticals. Dr. Rosenthal also served on an advisory board for Reata Pharmaceuticals, Biogen Pharmaceuticals, Biohaven Pharmaceuticals, Merck Healthcare KGaA, and as a one-time consultant for UCB Pharmaceuticals.

: Not applicable.